Cannabinoids in Glaucoma Patients: The Never-Ending Story

Journal of Clinical Medicine

Gianluca Guidi¹  Andrea Passani¹  Chiara Posarelli¹  AngelaTindara Sframeli¹  Laura Perciballi¹  Michele Figus¹  Marco Pellegrini² 

[1] Ophthalmology, Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, 56126 Pisa, Italy;Ophthalmology, Head and Neck Department, S.Orsola-Malpighi Teaching Hospital-University of Bologna, 40138 Bologna, Italy;

关键词: Cannabinoids;    glaucoma;    ocular hypertension;    intraocular pressure;    marijuana;    cannabis;   

DOI  :  10.3390/jcm9123978

来源: DOAJ

【 摘 要 】

Glaucoma is one of the principal causes of irreversible blindness worldwide. Yet, intraocular pressure (IOP) is the main modifiable risk factor for disease progression. In the never-ending challenge to develop new and effective drugs, several molecules have been tested as anti-glaucoma agents thanks to their pressure-lowering capabilities. Among these molecules, the cannabinoids have been investigated as possible anti-glaucoma drugs since the early 1970s. Cannabinoids are a large class of chemical compounds that exploit their effects by interaction with cannabinoid receptors 1 and 2. These receptors are widely expressed in the human retina where they may influence important functions such as photo-transduction, amacrine cell network maintenance, and IOP regulation. Therefore, in past years several studies have been conducted in order to assess the IOP lowering effects of cannabinoids. PRISMA guidelines have been used to perform a literature search on Pubmed and Scopus aiming to investigate the mechanism of IOP lowering effects and the potential benefits of orally administered, inhaled, topical, and intravenous cannabinoids in the treatment of glaucoma patients.

【 授权许可】

Unknown